Apontis Pharma AG provided revenue guidance for the year 2022. For the year, the Executive Board confirms its forecast of an increase in revenues of 8% to EUR 55.3 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.17 EUR | +2.38% | +4.88% | +74.36% |
04-05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
03-28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.97% | 661B | |
+26.74% | 566B | |
-6.65% | 352B | |
+19.35% | 332B | |
+3.35% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.22% | 145B |
- Stock Market
- Equities
- APPH Stock
- APPH Stock
- News Apontis Pharma AG
- Apontis Pharma AG Provides Revenue Guidance for the Year 2022